Despite positive clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant resistance from PBMs. These organizations are frequently erecting limitations to reimbursement, like steep expense criteria and PA that hinder patient availability. Analysts indicate that the